share_log

Nabriva Therapeutics (NASDAQ:NBRV) Stock Price Passes Below 50-Day Moving Average of $1.89

Nabriva Therapeutics (NASDAQ:NBRV) Stock Price Passes Below 50-Day Moving Average of $1.89

Nabriva Therapeutics（纳斯达克股票代码：NBRV）股价跌破50天移动平均线1.89美元
Defense World ·  2023/01/25 18:21

Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.89 and traded as low as $1.50. Nabriva Therapeutics shares last traded at $1.51, with a volume of 19,485 shares trading hands.

Nabriva Therapeutics plc（纳斯达克股票代码：NBRV — Get Rating）的股价在周二的交易中跌破了其五十天移动平均线。该股的五十天移动平均线为1.89美元，交易价格低至1.50美元。Nabriva Therapeutics股票最后一次交易价格为1.51美元，交易量为19,485股。

Analyst Upgrades and Downgrades

分析师升级和降级

Several brokerages recently weighed in on NBRV. Northland Securities lowered shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research report on Friday, January 6th. StockNews.com started coverage on Nabriva Therapeutics in a report on Wednesday. They set a "hold" rating on the stock.

最近有几家经纪公司对NBRV进行了权衡。Northland Securities在1月6日星期五的一份研究报告中将Nabriva Therapeutics的股票评级从 “跑赢大盘” 下调至 “表现不佳”。StockNews.com在周三的一份报告中开始报道Nabriva Therapeutics。他们对该股设定了 “持有” 评级。

Get
获取
Nabriva Therapeutics
纳布里瓦疗法
alerts:
警报：

Nabriva Therapeutics Stock Performance

Nabriva Therapeutics 股票

The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 1.40. The firm has a fifty day simple moving average of $1.89 and a 200 day simple moving average of $3.61. The company has a market cap of $46.26 million, a price-to-earnings ratio of -0.08 and a beta of 1.67.

该公司的债务与权益比率为0.02，流动比率为2.20，速动比率为1.40。该公司的五十天简单移动平均线为1.89美元，200天简单移动平均线为3.61美元。该公司的市值为4,626万美元，市盈率为-0.08，beta值为1.67。

Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) EPS for the quarter, missing the consensus estimate of ($4.03) by ($0.18). Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. The company had revenue of $9.15 million for the quarter, compared to analyst estimates of $10.68 million. On average, sell-side analysts expect that Nabriva Therapeutics plc will post -17.37 earnings per share for the current fiscal year.
Nabriva Therapeutics（纳斯达克股票代码：NBRV — Get Rating）上次公布季度财报是在11月10日星期四。这家生物技术公司公布了本季度每股收益（4.21美元），比市场普遍预期的（4.03美元）低了（0.18美元）。Nabriva Therapeutics的净利润率为负133.25％，负股本回报率为120.02％。该公司本季度的收入为915万美元，而分析师的估计为1,068万美元。平均而言，卖方分析师预计，Nabriva Therapeutics plc将在本财年公布每股收益为-17.37％。

Hedge Funds Weigh In On Nabriva Therapeutics

对冲基金对 Nabriva Therapeutics 进行了权衡

A hedge fund recently raised its stake in Nabriva Therapeutics stock. Renaissance Technologies LLC lifted its stake in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.23% of the company's stock.

一家对冲基金最近提高了其在Nabriva Therapeutics股票的股份。Renaissance Technologies LLC在向美国证券交易委员会提交的最新13F表文件中显示，该公司在第二季度将其在Nabriva Therapeutics plc（纳斯达克股票代码：NBRV — 获取评级）的股份提高了102.1％。该基金在此期间又收购了402,144股股票后，拥有这家生物技术公司的795,938股股票。截至最近报告期末，Renaissance Technologies LLC拥有Nabriva Therapeutics约0.13％的股份，价值14.5万美元。机构投资者和对冲基金拥有该公司0.23％的股票。

About Nabriva Therapeutics

关于纳布里瓦疗法

(Get Rating)

（获取评分）

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Nabriva Therapeutics Plc是一家生物制药公司，从事治疗严重感染的新型抗感染药物的研究、开发和商业化。其产品线包括Lefamulin、CONTEPO 和 BC-7013。该公司成立于 2005 年 10 月，总部位于爱尔兰都柏林。

Featured Articles

精选文章

  • Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
  • Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
  • How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
  • Is the Pain Over for Baudax Bio Investors after a 70% Spike?
  • Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
  • When Will Crane Holdings Take Flight?
  • 免费获取 StockNews.com 关于 Nabriva Therapeutics (NBRV) 的研究报告
  • Pliant Therapeutics 的差距上涨了 34%：还有更多上行空间？
  • 2023 年初的裁员将如何影响这5只生物技术股？
  • 在飙升70％之后，Baudax Bio投资者的痛苦结束了吗？
  • 火箭实验室在美国的首次发射会将股票送入平流层吗？
  • Crane Holdings 什么时候起飞？

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Nabriva Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Nabriva Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发